Citadel Advisors’s Palvella Therapeutics PVLA Stock Holding History

Citadel Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$972K	Buy	+7,800	New	+$814K	﹤0.01%	7719
2024 Q2	–	Sell	-3	Closed	-$37	–	15639
2024 Q1	$37	Sell	3 -51	-94%	-$710	﹤0.01%	14444
2023 Q4	$783	Hold	54	–	–	﹤0.01%	13943
2023 Q3	$1.28K	Hold	54	–	–	﹤0.01%	13887
2023 Q2	$712	Sell	54 -12	-18%	-$728	﹤0.01%	14059
2023 Q1	$5.17K	Buy	66 +15	+29%	+$1.74K	﹤0.01%	13886
2022 Q4	$4.26K	Buy	+51	New	+$4.1K	﹤0.01%	14114
2022 Q2	–	Sell	-191	Closed	-$46K	–	14313
2022 Q1	$46K	Buy	191 +32	+20%	+$8.41K	﹤0.01%	12849
2021 Q4	$48K	Sell	159 -830	-84%	-$266K	﹤0.01%	13276
2021 Q3	$409K	Buy	989 +18	+2%	+$6.27K	﹤0.01%	10359
2021 Q2	$298K	Buy	+971	New	+$213K	﹤0.01%	11291

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors's PVLA Position: Q1 2026 in Review

Citadel Advisors increased its Palvella Therapeutics (PVLA) stake by 677% in Q1 2026, buying an estimated $1.86M and bringing the position to 20,472 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #5578.

Citadel Advisors first reported a position in PVLA in Q4 2017 and has held it in 30 quarters since. The position peaked at $11.9M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Citadel Advisors held 20,472 shares of Palvella Therapeutics worth $2.55M as of Q1 2026.
Citadel Advisors bought 17,836 Palvella Therapeutics shares in Q1 2026, an estimated $1.86M.
Palvella Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5578 holding.
Citadel Advisors first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 30 quarters since.
Citadel Advisors's Palvella Therapeutics position peaked at $11.9M in Q3 2021.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.